Physician profile
Amer Alsoudi
NPI 1215519871
$2,925.25
in general payments reported to CMS, 2019-2025
12 companies · $1,659 in 2025
The $1,659 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $109 · 2023: $827 · 2024: $331 · 2025: $1,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063 · Travel and Lodging: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.92 |
| Travel and Lodging | $753.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,349.98 | 2022-2025 | Constellation, Unity, Finesse Sharkskin |
| Regeneron Healthcare Solutions, INC. | $388.66 | 2023-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $269.51 | 2022-2025 | Stellaris, Miebo, Stellaris |
| Tarsus Pharmaceuticals, INC. | $148.87 | 2025 | |
| New World Medical,INC. | $138.56 | 2025 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Rxsight INC | $127.39 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Genentech USA, INC. | $126.25 | 2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $117.65 | 2025 | Syfovre |
| Horizon Therapeutics Plc | $109.89 | 2023 | Tepezza |
| Astellas Pharma Global Development | $107.10 | 2025 | Izervay |
| Sight Sciences, INC. | $25.24 | 2022 | |
| Abbvie INC. | $16.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Alsoudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.